Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
Study sponsor: AIM ImmunoTech Inc. · AIM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-17Actual
Enrollment · participants80Actual
Source updated2025-01-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.